Loading…
The AVA Annual Conference is the nation’s premier veterinary event, covering all fields of veterinary science and in 2017 brought together over 920 veterinary professionals and 115 exhibitors.

We hope you will join us for the 2018 AVA Annual Conference in Brisbane, 13-18 May.    
Visit conference.ava.com.au to register.    To download a pdf file of the entire program click here.
avatar for Biopharm Australia Pty. Ltd.

Biopharm Australia Pty. Ltd.

Biopharm Australia pioneered the worldwide veterinary development of sodium pentosan polysulfate as a disease modifying osteoarthritis drug (DMOAD) under the brand Cartrophen. Founded in Australia in the 1980s, Biopharm Australia is a world leader in the research and development of sulfated polysaccharides for use in veterinary medicine and has ongoing research and development commitments in osteoarthritis, musculoskeletal disease and cancer. Cartophen Vet (100mg/mL) is approved in Australia, New Zealand, Ireland, Finland, Canada, Austria, Belgium, Denmark, the Netherlands, Poland, Norway, Iceland, Switzerland, Argentina, Chile, Brazil and some technically demanding jurisdictions such as Japan, France, Germany, Sweden and the United Kingdom. Cartrophen Equine Forte (250mg/mL) is approved for horses in Australia, New Zealand and the United Arab Emirate. The quality of Cartrophen products is assured by its testing laboratories that are accredited by Therapeutic Goods Administration (TGA) licensed and recognised internationally.